Dapiglutide Phase IIa: Safety, Modest Metabolic Signals but No Significant Weight Benefit at 12 Weeks

A randomized, double-blind phase IIa trial in adults with obesity evaluated weekly dapiglutide, described as a dual GLP-1/GLP-2 receptor agonist, versus placebo over 12 weeks. The study reported that the primary efficacy comparison for the higher dose did not reach statistical significance versus placebo (p=0.076): the estimated between-group difference in percentage weight change for 6 mg versus placebo was −2.1%. In that account, the main finding is that the tested doses did not show a statistically significant weight-loss advantage versus placebo within the study period.

The investigator-initiated, single-center 12-week phase IIa trial was conducted in Denmark and enrolled 54 adults with obesity randomized 1:1:1 to dapiglutide 4 mg, dapiglutide 6 mg, or placebo given as weekly injections. The primary endpoint was percentage change in body weight from baseline to week 12; the summary reports within-group reductions of −2.2% in the placebo arm, −2.9% with 4 mg, and −4.3% with 6 mg. It also highlights the magnitude of placebo-associated weight loss as a prominent feature of the dataset and a contextual factor for interpretation.

The study also describes secondary metabolic and anthropometric findings. It reports a greater HbA1c reduction in the 6 mg group versus placebo of 2.4 mmol/mol (p=0.006), presented as a secondary result rather than the primary efficacy outcome. By contrast, circulating lipid measures were described as not showing meaningful changes over the trial. The account notes that BMI and waist circumference reductions were observed in the higher-dose group, but that these signals did not remain statistically significant after adjustment for multiple testing. Overall, the secondary outcomes are depicted as showing a select glycemic change without broader lipid shifts, with anthropometric signals characterized as sensitive to statistical adjustment.

Tolerability findings center on gastrointestinal events as the most commonly reported adverse events, including reduced appetite (61%) and nausea (56%). Vomiting was reported in 11% of participants and described as similar between active treatment and placebo groups. No participants discontinued because of drug-related adverse effects. One fatal serious adverse event—small cell lung carcinoma with dissemination—occurred in the 6 mg group and was adjudicated as unrelated to trial participation. Across the 12-week exposure window, the overall safety and tolerability profile is described as generally well tolerated in this small, controlled study.

The report frames the study as a proof-of-concept evaluation and notes limitations including short duration, small sample size, and relatively large placebo-associated weight loss. It also states that larger, longer trials would be needed to further assess this dual-receptor approach, without presenting the current results as definitive. The work is presented as an initial human test of the agent that observed tolerability and selected metabolic signals while not demonstrating a statistically significant weight-loss advantage versus placebo over the trial period.

Key Takeaways:

• The primary weight endpoint was reported as not statistically significant versus placebo at 12 weeks for the higher dose.
• Within-group weight reductions were observed across arms, alongside a notable placebo-associated decline described as an interpretive challenge in the summary.
• A secondary HbA1c signal was reported for the higher-dose group, and the overall safety/tolerability findings were summarized as predominantly gastrointestinal with no drug-related discontinuations.